drugset / Trial / NCT02768220

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

NCT02768220

Phase 4 Withdrawn Northwell Health
RandomizedCrossoverOpen-labelTreatment

Summary

Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.

Timeline

Start
2017-12-01
Primary completion
2018-08
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule 25 mg
Subject Linagliptin Small molecule 5 mg

Indications